CCP
AEMD icon

Cardan Capital Partners’s Aethlon Medical AEMD Stock Holding History

Cardan Capital Partners’s Portfolio AEMD Stock Details AEMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-20
Closed -$32K – 251
2021
Q1 		$32K Hold
20
– – ﹤0.01% 238
2020
Q4 		$39K Buy
+20
New +$26.7K ﹤0.01% 226

Other funds holding AEMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CFN
Cordasco Financial Network Naples, Florida $138M AUM 10.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Cardan Capital Partners's AEMD Position: Q2 2021 in Review

Cardan Capital Partners sold out of Aethlon Medical (AEMD) in Q2 2021, closing a stake of 20 shares — an estimated $32K sold.

Cardan Capital Partners first reported a position in AEMD in Q4 2020 and held it in 2 quarters. The position peaked at $39K in Q4 2020. 16 funds tracked by Wall St. Rank hold AEMD as of Q2 2021.

  • Cardan Capital Partners reported no remaining Aethlon Medical position as of Q2 2021 after selling out during the quarter.
  • Cardan Capital Partners sold 20 Aethlon Medical shares in Q2 2021, an estimated $32K.
  • Cardan Capital Partners first reported a position in Aethlon Medical in Q4 2020 and held it in 2 quarters.
  • Cardan Capital Partners's Aethlon Medical position peaked at $39K in Q4 2020.
  • 16 funds tracked by Wall St. Rank held Aethlon Medical as of Q2 2021.

Based on Cardan Capital Partners's 13F filing for Q2 2021, filed 20 Jul 2021.